Cadrenal Therapeutics, Inc. (CVKD)
1.09
+0.09
(+9.00%)
USD |
NASDAQ |
Nov 06, 10:36
Cadrenal Therapeutics Enterprise Value : 0.7105M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 0.7105M |
| November 04, 2026 | 0.8964M |
| November 03, 2026 | 1.113M |
| November 02, 2026 | 0.8344M |
| October 30, 2026 | 0.664M |
| October 29, 2026 | 0.5351M |
| October 28, 2026 | 0.5491M |
| October 27, 2026 | 0.5317M |
| October 26, 2026 | 0.4316M |
| October 23, 2026 | 0.5866M |
| October 22, 2026 | 0.6175M |
| October 21, 2026 | 0.7725M |
| October 20, 2026 | 0.8344M |
| October 19, 2026 | 0.8964M |
| October 16, 2026 | 0.9894M |
| October 15, 2026 | 0.6175M |
| October 14, 2026 | 0.7725M |
| October 13, 2026 | 0.7012M |
| October 12, 2026 | 0.3151M |
| October 09, 2026 | 0.4319M |
| October 08, 2026 | 0.4924M |
| October 07, 2026 | 0.6247M |
| October 06, 2026 | 0.6795M |
| October 05, 2026 | 0.5426M |
| October 02, 2026 | 0.5252M |
| Date | Value |
|---|---|
| October 01, 2026 | 0.6175M |
| September 30, 2026 | 0.9584M |
| September 29, 2026 | 0.9894M |
| September 28, 2026 | 1.082M |
| September 25, 2026 | 1.175M |
| September 24, 2026 | 1.330M |
| September 23, 2026 | 1.702M |
| September 22, 2026 | 1.082M |
| September 21, 2026 | 0.9894M |
| September 18, 2026 | 0.9274M |
| September 17, 2026 | 1.082M |
| September 16, 2026 | 0.9584M |
| September 15, 2026 | 0.8654M |
| September 14, 2026 | 0.8964M |
| September 11, 2026 | 0.9894M |
| September 10, 2026 | 1.268M |
| September 09, 2026 | 1.299M |
| September 08, 2026 | 1.330M |
| September 04, 2026 | 1.392M |
| September 03, 2026 | 1.578M |
| September 02, 2026 | 1.733M |
| September 01, 2026 | 2.291M |
| August 31, 2026 | 3.034M |
| August 28, 2026 | 2.384M |
| August 27, 2026 | 2.461M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.834B |
| Corcept Therapeutics, Inc. | 7.472B |
| Veru, Inc. | 12.02M |
| Johnson & Johnson | 682.93B |
| Eli Lilly & Co. | 1.329T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.323M |
| Total Expenses (Quarterly) | 3.323M |
| EPS Diluted (Quarterly) | -1.140 |
| Earnings Yield | -449.8% |
| Normalized Earnings Yield | -449.79 |